![PARP-1](https://www.adcreviews.com/wp-content/uploads/2022/09/PARP-1-196x160.png)
FDA withdraws approval of 3 PARP inhibitors to treat ovarian cancer
According to the FDA’s official website, the indications of three PARP inhibitors for the last-line treatment of ovarian cancer have been withdrawn, namely AstraZeneca’s olaparib,
According to the FDA’s official website, the indications of three PARP inhibitors for the last-line treatment of ovarian cancer have been withdrawn, namely AstraZeneca’s olaparib,